OHMONDE
Just inLouis Vuitton’s make-up puts on the Monogram: Ghesquière and McGrath’s Dune and InfrarougeMulberry: sales up 18%, a £33 million loss — and why both are trueLamborghini’s Temerario Spyder: the first raging bull with a folding hard roofLa Madrague: Brigitte Bardot’s house on the bay of CanoubiersThe New Year editions: Damien Hirst’s Dom Pérignon, Rémy Martin’s centaur and a countdown for the Sun KingThe advent calendars of winter 2026: from YSL’s $400 chest to Dior’s $8,200 trunkLOEWE × Tim Burton: The Nightmare Before Christmas, from a $320 perfume to bags from $8,950Anthropic prices the largest IPO on record — $81 billion, and trading starts todayThe rounds Wall Street is talking about: OpenAI at $1.25 trillion — and four more billion-dollar betsHow to find investors for a startup — from the first cheque to Series AJust inLouis Vuitton’s make-up puts on the Monogram: Ghesquière and McGrath’s Dune and InfrarougeMulberry: sales up 18%, a £33 million loss — and why both are trueLamborghini’s Temerario Spyder: the first raging bull with a folding hard roofLa Madrague: Brigitte Bardot’s house on the bay of CanoubiersThe New Year editions: Damien Hirst’s Dom Pérignon, Rémy Martin’s centaur and a countdown for the Sun KingThe advent calendars of winter 2026: from YSL’s $400 chest to Dior’s $8,200 trunkLOEWE × Tim Burton: The Nightmare Before Christmas, from a $320 perfume to bags from $8,950Anthropic prices the largest IPO on record — $81 billion, and trading starts todayThe rounds Wall Street is talking about: OpenAI at $1.25 trillion — and four more billion-dollar betsHow to find investors for a startup — from the first cheque to Series A
Health · Aesthetic medicine — Beijing
by Ohmonde Health Desk
23 October 2026
English / Русский

Galderma’s ready-to-use neuromodulator Relfydess is approved in ChinaГотовый к применению нейромодулятор Relfydess от Galderma одобрен в Китае

China’s regulator cleared the liquid toxin for frown lines; launch there is planned for the second half of 2027.Китайский регулятор разрешил жидкий токсин для коррекции межбровных морщин; запуск в Китае запланирован на вторую половину 2027 года.

Galderma’s ready-to-use neuromodulator Relfydess is approved in China
Illustrative · Ousa Chea · Unsplash

China’s National Medical Products Administration approved Galderma’s Relfydess (relabotulinumtoxinA) for the temporary improvement of moderate-to-severe frown lines in adults, the company announced on 23 October 2026.

Galderma describes Relfydess as the first ready-to-use liquid neuromodulator made with its PEARL technology; it is already authorised in more than 35 markets. The company expects to launch it in China in the second half of 2027 — one of the largest markets for injectable aesthetics.

Национальное управление медицинской продукции Китая одобрило Relfydess (релаботулинумтоксин A) компании Galderma для временной коррекции умеренных и выраженных межбровных морщин у взрослых, сообщила компания 23 октября 2026 года.

Galderma называет Relfydess первым готовым к применению жидким нейромодулятором, созданным по технологии PEARL; он уже разрешён более чем на 35 рынках. Компания рассчитывает начать продажи в Китае — одном из крупнейших рынков инъекционной косметологии — во второй половине 2027 года.

SourcesИсточники

  1. Galderma — Relfydess receives approval in China
  2. BioSpectrum Asia — China approves Relfydess

OHMONDE writes its stories in its own words from the sources above. Spotted an error? hello@ohmonde.com

Read nextЧитайте также